Kaimen Rigor reviewed

Rigor-Reviewed Manuscript

A Randomized Trial of Drug Route in Out-of-Hospital Cardiac Arrest.

Name: Kaimen Rigor review — A Randomized Trial of Drug Route in Out-of-Hospital Cardiac Arrest.
Item: A Randomized Trial of Drug Route in Out-of-Hospital Cardiac Arrest.
Rating: 59
Author: Alpha1

Couper K, Ji C, Deakin CD, Fothergill RT, Nolan JP, Long JB, Mason JM, Michelet F, Norman C, Nwankwo H, Quinn T, Slowther AM, Smyth MA, Starr KR, Walker A, Wood S, Bell S, Bradley G, Brown M, Brown S, Burrow E, Charlton K, Claxton Dip A, Dra'gon V, Evans C, Falloon J, Foster T, Kearney J, Lang N, Limmer M, Mellett-Smith A, Miller J, Mills C, Osborne R, Rees N, Spaight RES, Squires GL, Tibbetts B, Waddington M, Whitley GA, Wiles JV, Williams J, Wiltshire S, Wright A, Lall R, Perkins GD, PARAMEDIC-3 Collaborators

Paper source

Read full text (PMC)

Embed this Rigor badge

Kaimen Rigor review — 3.75★ (Adequate), 0 critical, 4 high issues for “A Randomized Trial of Drug Route in Out-of-Hospital Cardiac Arrest.”

Links back to this Kaimen Rigor review.

Alpha1 Editorial

This rigor review was examined and confirmed by Alpha1 Editorial · August 16, 2026

Read alongside

A Randomized Trial of Drug Route in Out-of-Hospital Cardiac Arrest.

Read full text (PMC)

DOI

10.1056/NEJMoa2407780

Share this Kaimen Rigor review

Post on X Share on LinkedIn Share via Email

Embed this Rigor badge

<a href="https://alpha1science.com/verify/52f8c923-78c3-453e-ad72-cb837f2c2d93" target="_blank" rel="noopener">
  <img src="https://alpha1science.com/verify/52f8c923-78c3-453e-ad72-cb837f2c2d93/badge" alt="Kaimen Rigor review — 3.75★ (Adequate), 0 critical, 4 high issues for “A Randomized Trial of Drug Route in Out-of-Hospital Cardiac Arrest.”" width="440" height="104" style="max-width:100%;height:auto" />
</a>

Every embed links back to this Kaimen Rigor review.

Record fingerprint

0022d049b801c0155e9dec24f92eeec74a899f9faa7e5c945cf13f482f8166b2

Verify via API

Issued Aug 16, 2026Engine 7.39.0

Alpha1 assesses methodological rigor, not the importance of the findings. See how we calibrate →

Alpha¹ by Kaimen

Fetching the latest research

Kaimen Rigor reviewed

Rigor-Reviewed Manuscript

A Randomized Trial of Drug Route in Out-of-Hospital Cardiac Arrest.

Paper source

A Randomized Trial of Drug Route in Out-of-Hospital Cardiac Arrest.

Read full text (PMC)

Embed this Rigor badge

Links back to this Kaimen Rigor review.

Alpha1 Editorial

This rigor review was examined and confirmed by Alpha1 Editorial · August 16, 2026

Kaimen Rigor review

Kaimen Rigor reviewed

3.75 / 5

Adequate — real issues to address

Interventional Study

Critical

High-priority

How this rating was calculated▸

Started at 5★ — deductions

IntegrityIntegrity concern−0.5★
StatisticsPrinted percentage does not match its own count (capped)−0.25★
ReportingData & code availability partially met−0.25★
CitationsRetracted reference cited−0.25★

Model-reported confidence: highReviewer agreement: highEngine: 7.39.0Source: full text

Not verified in this report

The numeric-impossibility checks (GRIM/GRIMMER/DEBIT/SPRITE) did not run: 2 reported means were read, and their group size is not stated where the values are printed (this source has no machine-readable table structure). These checks need the count the mean was averaged over, so none was performed.
No data or code availability links were detected to verify.

Biggest issues

01Cites retracted work
highAvailabilityrecomputedFull detail
Retraction
“Intraosseous versus intravenous vascular access in upper extremity among adults with out-of-hospital cardiac arrest: cluster randomised clinical trial (VICTOR trial)”
Reference 27Find in source
02Printed percentage does not match its own count
mediumArithmeticrecomputedFull detail
0.33% does not match the reported count 1/3040
“1/3040 (0.33)”
Table 3Find in source

Findings by category

201ArithmeticNumerical inconsistencies 02OverreachNone found 03AuthenticityNone found 104DisclosureReporting gaps 105AvailabilityBroken references and links · partly checked 06Copyedit5 minor suggestions

This Kaimen Rigor review uses Kaimen Rigor reviewers trained on a curated corpus of high-fidelity and retracted papers, with expert supervision and curation. It can still make mistakes; verify each finding against the source before relying on it.

This is a well-conducted and transparently reported randomized controlled trial with a rigorous design, clear ethical approvals, and appropriate statistical analysis. The main weakness is the lack of a concrete data availability statement, and there are minor copyedit issues including a typo and an internal inconsistency in the total N reported in Table 1.

Both reviewers agreed on study type (interventional) and on all dimension statuses except data code availability, where one found a vague statement and the other found none; the synthesized status is warn. The statistics verification component checked only a subset of tests (4 tests, 3 consistent, 1 inconsistent), so the paper's statistics are not fully verified. The citation component flagged one retracted reference.

Numerical inconsistencies

2 findings · worst medium

Values that contradict each other or are impossible for the stated sample: recomputed p-values and test statistics, GRIM/GRIMMER checks on summary numbers, percentages against their own counts, totals against their parts, and estimates against their own confidence intervals.

Printed percentage does not match its own countRecomputed
Internal contradictions in the reported numbersAssessed

Recomputed 3 tests: 3 consistent, 0 inconsistent; 1 recomputed directly from the reported test statistics, 2 via agent-written checks. 1 printed percentage that does not match its own count.

Overstated conclusions

None found

Conclusions that reach past what the paper's own results support — including a significance claim that no longer holds when the statistic is recomputed, and efficacy resting on an unvalidated surrogate endpoint.

Checked — nothing surfaced.

4 major claims checked against the paper's own evidence: all adequately supported.

Efficacy claim is anchored to an adequate endpoint and a meaningful effect.

Data authenticity concerns

None found

An adversarial read for patterns associated with data that may not be genuine: results that look too clean, implausibly large effects, duplicated data or images, and methods that do not match the results reported.

Checked — nothing surfaced.

Reporting gaps

1 finding · worst medium

Required detail the manuscript never states — study design, biological variables, ethics approval and consent, key resources, statistical reporting, data and code availability, and overall transparency.

Data/code availability incompleteAssessed

Eight Dimensions7 pass · 1 warn

The paper cites prior trials and observational studies on drug administration routes in cardiac arrest, acknowledges the limitations of observational studies (e.g., resuscitation time bias), and states the need for randomized trials as highlighted by the International Liaison Committee on Resuscitation. The hypothesis follows logically from the premise that intraosseous access may facilitate more rapid drug administration and improve outcomes.

Sub-criteria

prior work citedADEQUATE

premise rationaleADEQUATE

limitations addressedADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

The introduction establishes a clear scientific premise, citing prior observational studies and trials, and articulates the rationale for the trial.

Evidence

“Recent trials have explored the clinical effectiveness of cardiac arrest drugs. , The effects of which are highly time-dependent, suggesting earlier drug administration may improve outcomes.”

Introduction ¶1Find in source

“Observational studies comparing intraosseous and intravenous drug administration in cardiac arrest report similar or worse outcomes in patients receiving intraosseous drugs, but these studies are challenging to interpret as intraosseous access is typically attempted after a failed intravenous access attempt confounding findings because of resuscitation time bias.”

Introduction ¶2Find in source

“Given ongoing uncertainty as to the optimal drug route in adult cardiac arrest, the International Liaison Committee on Resuscitation highlighted the urgent need for randomized trials to evaluate the clinical effectiveness of the intraosseous access route.”

Introduction ¶3Find in source

PASSReviewer 2· 90% conf

The introduction establishes a clear scientific premise, citing prior observational studies and trials, and articulates a logical rationale for the trial.

Evidence

“In observational studies and one small randomized trial, the intraosseous, compared with the intravenous route, facilitated more rapid drug administration, particularly when the proximal tibial site is used.”

Introduction ¶1Find in source

Introduction ¶2Find in source

Introduction ¶1Find in source

Randomization used sequentially numbered, tamper-proof, opaque envelopes, stratified by site, ensuring allocation concealment. The trial is open-label, which is acknowledged and justified due to the nature of the intervention. A sample size calculation was performed (14972 patients to detect a 1% difference), though recruitment was stopped early. Inclusion/exclusion criteria are clearly stated. The analysis population (intention-to-treat) and handling of missing data (multiple imputation) are described.

Sub-criteria

controlsN/A

power analysisADEQUATE

blinding levelsADEQUATE

outlier handlingADEQUATE

randomization unitADEQUATE

inclusion exclusionADEQUATE

randomization methodADEQUATE

replicate distinctionN/A

independent replicationN/A

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 95% conf

The trial design is rigorous: randomized, stratified by site, with a clear randomization method, pre-specified inclusion/exclusion criteria, and a detailed statistical analysis plan.

Evidence

“At the time a patient was identified as requiring vascular access, they were randomized in a 1:1 ratio to the intraosseous or intravenous group using a sequentially numbered, tamper-proof, opaque envelope system.”

MethodsFind in source

“Based on PARAMEDIC2 trial data, 14972 patients were required to detect a difference in the 30-day survival status of 1% (3.2% to 4.2%; 5% significance level; 90% power).”

Statistical analysisFind in source

“Adults (≥ 18 years of age), who sustained an out-of-hospital cardiac arrest, were attended by trial-trained paramedics and who required vascular access for drug administration during ongoing cardiopulmonary resuscitation were eligible for the trial. We excluded individuals with known or apparent pregnancy.”

MethodsFind in source

PASSReviewer 2· 95% conf

The trial design is rigorous with clear randomization, allocation concealment, pre-specified analysis, and appropriate handling of the open-label nature.

Evidence

MethodsFind in source

“Based on PARAMEDIC2 trial data, 14972 patients were required to detect a difference in the 30-day survival status of 1% (3.2% to 4.2%; 5% significance level; 90% power).”

Statistical analysisFind in source

“The open label nature of the trial precluded blinding of outcome assessors.”

MethodsFind in source

The paper reports age (mean ± SD), sex (male/female counts and percentages), and other baseline characteristics such as location, initial rhythm, and etiology. Since both sexes are enrolled, a justification for single-sex is not applicable. Age and health status are captured through the baseline table.

Sub-criteria

demographicsADEQUATE

sex reportedADEQUATE

sex justifiedN/A

age weight healthADEQUATE

housing conditionsN/A

species strain sourceN/A

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

Demographic and baseline characteristics are well reported, including age, sex, and other relevant variables.

Evidence

“Age mean ± standard deviation - yr | 67.8 ± 16.3 | 68.3 ± 15.9 | 68.1 ± 16.1”

Table 1Find in source

“Male | 1941 (63.9%) | 1951 (64.1%) | 3892 (64.0%)”

Table 1Find in source

PASSReviewer 2· 90% conf

Key demographic and clinical characteristics are reported, including age, sex, and cardiac arrest characteristics.

Evidence

“Age mean ± standard deviation - yr | 67.8 ± 16.3 | 68.3 ± 15.9 | 68.1 ± 16.1”

Table 1Find in source

“Male | 1941 (63.9%) | 1951 (64.1%) | 3892 (64.0%)”

Table 1Find in source

The trial protocol was approved by the South Central–Oxford C Research Ethics Committee (21/SC/0178) and the Health Research Authority Confidentiality Advisory Group (20/CAG/0092). Due to the emergency setting, initial enrolment without consent was approved, and consent for ongoing data collection was sought from survivors or proxies. The study adhered to Good Clinical Practice and the Declaration of Helsinki.

Sub-criteria

iacuc statementN/A

informed consentADEQUATE

irb ethics statementADEQUATE

regulatory complianceADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 95% conf

Ethical approval is clearly documented with named committees and protocol numbers, and consent procedures are described.

Evidence

“The trial protocol was approved by the South Central–Oxford C Research Ethics Committee (21/SC/0178) and the Health Research Authority Confidentiality Advisory Group (20/CAG/0092).”

MethodsFind in source

“Due to the time-critical nature of treatment in cardiac arrest, the Research Ethics Committee approved a process of initial enrolment without consent in accordance with local legislation (details provided in the ). Consent for ongoing data collection was subsequently sought from survivors or a proxy decision-maker if the individual lacked capacity.”

MethodsFind in source

“The study adhered to Good Clinical Practice guidelines, local regulations, and the ethical principles described in the Declaration of Helsinki.”

MethodsFind in source

PASSReviewer 2· 95% conf

Ethical approval is clearly documented with named committees, and consent procedures are described.

Evidence

“The trial protocol was approved by the South Central–Oxford C Research Ethics Committee (21/SC/0178) and the Health Research Authority Confidentiality Advisory Group (20/CAG/0092).”

MethodsFind in source

“The study adhered to Good Clinical Practice guidelines, local regulations, and the ethical principles described in the Declaration of Helsinki.”

MethodsFind in source

The trial involves drugs (epinephrine, amiodarone) administered during cardiac arrest; these are named, and doses are reported in Table 2. The statistical software (SAS version 9.4) is identified. No antibodies, cell lines, or other bench reagents are used, so those criteria are not applicable.

Sub-criteria

mycoplasma testingN/A

reagents identifiedADEQUATE

organisms identifiedN/A

antibodies identifiedN/A

cell line authenticationN/A

software tools identifiedADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 85% conf

The investigational product (epinephrine and amiodarone) is identified, and statistical software is specified.

Evidence

paraphrase[Table 2]

“Epinephrine | Administered- – no. (%) | 2866 (94.3%) | 2836 (93.2%) | 5702 (93.8%) | Dose (mg)- median (IQR) | 5.0 (3.1, 8.0) | 5.0 (3.0, 8.0) | 5.0 (3.0, 8.0)”

“Data management and analysis was performed with Statistical Analysis Systems (SAS), version 9.4.”

Statistical analysisFind in source

PASSReviewer 2· 85% conf

The investigational product (epinephrine) and other drugs are identified, and statistical software is specified.

Evidence

paraphrase[Table 2]

“Epinephrine | Administered- – no. (%) | 2866 (94.3%) | 2836 (93.2%) | 5702 (93.8%)”

“Data management and analysis was performed with Statistical Analysis Systems (SAS), version 9.4.”

Statistical analysisFind in source

The primary outcome was analyzed using logistic regression, with adjusted and unadjusted odds ratios and 95% CIs. Exact p-values are reported for the primary outcome (p=0.741) and for the adverse event analysis (p=0.968). Effect sizes are reported with confidence intervals throughout. The statistical software is identified. Data presentation includes per-group n and appropriate measures (e.g., medians with IQR). Mathematical plausibility checks were not performed due to the large sample size and continuous outcomes, but no obvious inconsistencies were noted.

Sub-criteria

tests namedADEQUATE

exact p valuesADEQUATE

effect sizes ciADEQUATE

data presentationADEQUATE

software identifiedADEQUATE

assumptions verifiedADEQUATE

mathematical plausibilityN/A

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

Statistical methods are appropriate and well-described, with exact p-values for the primary outcome and effect sizes with confidence intervals.

Evidence

“Survival at 30-days occurred in 137 of 3030 (4.5%) in the intraosseous group and 155 of 3034 (5.1%) in the intravenous group (adjusted odds ratio, 0.945, 95% confidence interval (CI) 0.676-1.322, p=0.741).”

ResultsFind in source

“0.880 (0.695, 1.113) | 0.945 (0.676, 1.322), p=0.741”

Table 3Find in source

“Data management and analysis was performed with Statistical Analysis Systems (SAS), version 9.4.”

Statistical analysisFind in source

PASSReviewer 2· 90% conf

Statistical methods are appropriate and well-described, with effect sizes and confidence intervals reported; p-values are exact where reported.

Evidence

ResultsFind in source

“Return to spontaneous circulation (ROSC) anytime – no./total no. (%) | 1092/3031 (36.0%) | 1186/3035 (39.1%) | -3.0% (-5.5%, -0.6%) | -3.2% (-5.9%, - 0.6%) | 0.878 (0.791, 0.974) | 0.863 (0.765, 0.974)”

Table 3Find in source

“Data management and analysis was performed with Statistical Analysis Systems (SAS), version 9.4.”

Statistical analysisFind in source

The paper mentions that the protocol and statistical analysis plan are available in the Supplementary Appendix, but does not provide a clear data availability statement for the trial data. There is no mention of a repository deposit or accession numbers. Since this is a clinical trial with patient-level data, managed access would be acceptable, but the paper does not specify a mechanism.

Sub-criteria

code sharingN/A

accession numbersN/A

repository depositNOT REPORTED

data availability statementINADEQUATE

Per reviewer (2) — the votes behind the verdict

WARNReviewer 1· 80% conf

A data availability statement is present but vague, lacking a concrete access mechanism.

Evidence

“The protocol, developed by the trial investigators, has been published previously and is available, together with the statistical analysis plan, in the .”

MethodsFind in source

absence[Whole paper]

No repository deposit mentioned.

WARNReviewer 2· 80% conf

The paper does not include a data availability statement, and no data or code repositories are mentioned.

Evidence

absence[Entire paper]

No data availability statement is present in the paper.

The trial is registered (ISRCTN14223494). Methods are described in sufficient detail for replication. Limitations are explicitly discussed, including early termination, lack of blinding, and potential biases. Conclusions are proportional to the findings, acknowledging the trial was underpowered. Funding and conflicts of interest are disclosed.

Sub-criteria

funding coiADEQUATE

trial registrationADEQUATE

reporting guidelineINADEQUATE

methods completenessADEQUATE

all outcomes reportedADEQUATE

limitations discussedADEQUATE

conclusions proportionalADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

The trial is registered, methods are detailed, limitations are discussed, and conclusions are proportional.

Evidence

“Trial registration: ISRCTN14223494”

AbstractFind in source

“Our trial, the largest currently planned, was terminated early because of lower-than-anticipated recruitment, so is under-powered to detect a 1% difference between groups for the primary outcome.”

Discussion ¶4Find in source

“This study was funded by the National Institute for Health and Care Research Health Technology Assessment programme (NIHR131105).”

FundingFind in source

PASSReviewer 2· 90% conf

The paper is transparent, with trial registration, detailed methods, discussion of limitations, and proportional conclusions.

Evidence

“Trial registration: ISRCTN14223494”

AbstractFind in source

“Our trial has several additional limitations. We did not collect information on resuscitation quality, because of the pragmatic nature of the trial and the challenges of collecting these data.”

Discussion ¶4Find in source

“This study was funded by the National Institute for Health and Care Research Health Technology Assessment programme (NIHR131105).”

FundingFind in source

Registered (1 ID: ISRCTN). No reporting guideline cited.

Broken references and links

1 finding · worst high

References checked against Crossref, OpenAlex and Retraction Watch for retractions and resolvability, plus declared data and code links probed for whether they resolve to content matching the paper.

Cites retracted workRecomputed

Checked 30 references by DOI: 28 verified — 1 retracted, 1 no DOI (shown, not verified).

Copyediting

5 minor

Wording, consistency and formatting errors that need correcting before submission.

No major wording or formatting errors. 5 minor suggestions below.

5 copyedit issues flagged: mostly consistency, clarity, typo.

Kaimen Rigor Action ItemsFinal pass before journal submission

The published work is robust and generally trustworthy, but readers should weigh the minor data availability gap and the internal inconsistency in the reported total N. The retracted citation should be noted as a concern. No erratum is urgently required, but a correction for the N discrepancy and a clearer data availability statement would strengthen the record.

1.
HIGHrigor
Correct the internal inconsistency in the total number of randomized participants: Table 1 header states N=6086 while the text and Table 2 state N=6082. Verify the correct total and update Table 1 accordingly.
An internal contradiction in the primary denominator undermines the credibility of the reported results and could warrant a correction.
2.
HIGHdata code
Add a clear data availability statement in the Methods or a dedicated section, specifying a managed-access route (e.g., via the Warwick Clinical Trials Unit data access committee) with conditions and timeframe.
The current statement is vague or missing, and a concrete mechanism is expected for patient-level trial data.
3.
HIGHreporting
Remove or replace the retracted citation: 'Intraosseous versus intravenous vascular access in upper extremity among adults with out-of-hospital cardiac arrest: cluster randomised clinical trial (VICTOR trial)' (DOI 10.1136/bmj-2024-079878).
Citing a retracted paper is a serious integrity issue that must be corrected.
4.
HIGHcopyedit
Fix the incomplete sentence in Methods, Trial design and oversight: 'available, together with the statistical analysis plan, in the .' should read 'available in the Supplementary Appendix.'
The placeholder text is a clarity issue that also affects the data availability statement.
5.
MEDIUMcopyedit
Correct the typo in author affiliations: 'North Eest Ambulance Service' should be 'North East Ambulance Service'.
A typo in an affiliation is a minor but visible error.
6.
MEDIUMreporting
Explicitly state adherence to the CONSORT reporting guideline in the Methods or provide a CONSORT checklist.
Explicitly mentioning CONSORT strengthens reporting transparency.
7.
MEDIUMreporting
Provide a CONSORT flow diagram as a figure to improve reporting transparency.
A flow diagram is a standard element of trial reporting that is currently missing.
8.
MEDIUMstatistics
Clarify the handling of missing data for the primary outcome in the statistical analysis section, specifying the variables used in the multiple imputation model.
The paper mentions multiple imputation but does not detail the imputation model, which is important for reproducibility.
9.
MEDIUMreporting
Provide a link or DOI to the full protocol and statistical analysis plan in the manuscript text.
The current reference is incomplete and should be made explicit for readers.
10.
LOWcopyedit
Rephrase the sentence in Methods, Statistical Analysis: 'We planned to recruit 15,000 patients. Based on PARAMEDIC2 trial data, 14972 patients were required' for clarity.
The sentence structure is awkward and could be clearer.
11.
LOWreporting
Consider reporting exact p-values for all secondary outcomes, even though confidence intervals are provided.
Exact p-values enhance statistical transparency.
12.
LOWreporting
Add a note on the generalizability of the findings given the early termination, possibly in the abstract.
Highlighting the early termination in the abstract would help readers interpret the results.

Full text (42,297 chars)Analyzed: Aug 16, 2026

Start the discussion on JRNLClub

Community discussion on jrnlclub.com

Read alongside

A Randomized Trial of Drug Route in Out-of-Hospital Cardiac Arrest.

Read full text (PMC)

DOI

10.1056/NEJMoa2407780

Share this Kaimen Rigor review

Post on X Share on LinkedIn Share via Email

Embed this Rigor badge

<a href="https://alpha1science.com/verify/52f8c923-78c3-453e-ad72-cb837f2c2d93" target="_blank" rel="noopener">
  <img src="https://alpha1science.com/verify/52f8c923-78c3-453e-ad72-cb837f2c2d93/badge" alt="Kaimen Rigor review — 3.75★ (Adequate), 0 critical, 4 high issues for “A Randomized Trial of Drug Route in Out-of-Hospital Cardiac Arrest.”" width="440" height="104" style="max-width:100%;height:auto" />
</a>

Every embed links back to this Kaimen Rigor review.

Record fingerprint

0022d049b801c0155e9dec24f92eeec74a899f9faa7e5c945cf13f482f8166b2

Verify via API

Issued Aug 16, 2026Engine 7.39.0

Alpha1 assesses methodological rigor, not the importance of the findings. See how we calibrate →

Kaimen Rigor review

Kaimen Rigor reviewed

3.75 / 5

Adequate — real issues to address

Interventional Study

Critical

High-priority

How this rating was calculated▸

Started at 5★ — deductions

IntegrityIntegrity concern−0.5★
StatisticsPrinted percentage does not match its own count (capped)−0.25★
ReportingData & code availability partially met−0.25★
CitationsRetracted reference cited−0.25★

Model-reported confidence: highReviewer agreement: highEngine: 7.39.0Source: full text

Not verified in this report

The numeric-impossibility checks (GRIM/GRIMMER/DEBIT/SPRITE) did not run: 2 reported means were read, and their group size is not stated where the values are printed (this source has no machine-readable table structure). These checks need the count the mean was averaged over, so none was performed.
No data or code availability links were detected to verify.

Biggest issues

01Cites retracted work
highAvailabilityrecomputedFull detail
Retraction
“Intraosseous versus intravenous vascular access in upper extremity among adults with out-of-hospital cardiac arrest: cluster randomised clinical trial (VICTOR trial)”
Reference 27Find in source
02Printed percentage does not match its own count
mediumArithmeticrecomputedFull detail
0.33% does not match the reported count 1/3040
“1/3040 (0.33)”
Table 3Find in source

Findings by category

Numerical inconsistencies

2 findings · worst medium

Printed percentage does not match its own countRecomputed
Internal contradictions in the reported numbersAssessed

Recomputed 3 tests: 3 consistent, 0 inconsistent; 1 recomputed directly from the reported test statistics, 2 via agent-written checks. 1 printed percentage that does not match its own count.

Overstated conclusions

None found

Checked — nothing surfaced.

4 major claims checked against the paper's own evidence: all adequately supported.

Efficacy claim is anchored to an adequate endpoint and a meaningful effect.

Data authenticity concerns

None found

Checked — nothing surfaced.

Reporting gaps

1 finding · worst medium

Data/code availability incompleteAssessed

Eight Dimensions7 pass · 1 warn

Sub-criteria

prior work citedADEQUATE

premise rationaleADEQUATE

limitations addressedADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

The introduction establishes a clear scientific premise, citing prior observational studies and trials, and articulates the rationale for the trial.

Evidence

“Recent trials have explored the clinical effectiveness of cardiac arrest drugs. , The effects of which are highly time-dependent, suggesting earlier drug administration may improve outcomes.”

Introduction ¶1Find in source

Introduction ¶2Find in source

Introduction ¶3Find in source

PASSReviewer 2· 90% conf

The introduction establishes a clear scientific premise, citing prior observational studies and trials, and articulates a logical rationale for the trial.

Evidence

Introduction ¶1Find in source

Introduction ¶2Find in source

Introduction ¶1Find in source

Sub-criteria

controlsN/A

power analysisADEQUATE

blinding levelsADEQUATE

outlier handlingADEQUATE

randomization unitADEQUATE

inclusion exclusionADEQUATE

randomization methodADEQUATE

replicate distinctionN/A

independent replicationN/A

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 95% conf

The trial design is rigorous: randomized, stratified by site, with a clear randomization method, pre-specified inclusion/exclusion criteria, and a detailed statistical analysis plan.

Evidence

MethodsFind in source

“Based on PARAMEDIC2 trial data, 14972 patients were required to detect a difference in the 30-day survival status of 1% (3.2% to 4.2%; 5% significance level; 90% power).”

Statistical analysisFind in source

MethodsFind in source

PASSReviewer 2· 95% conf

The trial design is rigorous with clear randomization, allocation concealment, pre-specified analysis, and appropriate handling of the open-label nature.

Evidence

MethodsFind in source

“Based on PARAMEDIC2 trial data, 14972 patients were required to detect a difference in the 30-day survival status of 1% (3.2% to 4.2%; 5% significance level; 90% power).”

Statistical analysisFind in source

“The open label nature of the trial precluded blinding of outcome assessors.”

MethodsFind in source

Sub-criteria

demographicsADEQUATE

sex reportedADEQUATE

sex justifiedN/A

age weight healthADEQUATE

housing conditionsN/A

species strain sourceN/A

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

Demographic and baseline characteristics are well reported, including age, sex, and other relevant variables.

Evidence

“Age mean ± standard deviation - yr | 67.8 ± 16.3 | 68.3 ± 15.9 | 68.1 ± 16.1”

Table 1Find in source

“Male | 1941 (63.9%) | 1951 (64.1%) | 3892 (64.0%)”

Table 1Find in source

PASSReviewer 2· 90% conf

Key demographic and clinical characteristics are reported, including age, sex, and cardiac arrest characteristics.

Evidence

“Age mean ± standard deviation - yr | 67.8 ± 16.3 | 68.3 ± 15.9 | 68.1 ± 16.1”

Table 1Find in source

“Male | 1941 (63.9%) | 1951 (64.1%) | 3892 (64.0%)”

Table 1Find in source

Sub-criteria

iacuc statementN/A

informed consentADEQUATE

irb ethics statementADEQUATE

regulatory complianceADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 95% conf

Ethical approval is clearly documented with named committees and protocol numbers, and consent procedures are described.

Evidence

“The trial protocol was approved by the South Central–Oxford C Research Ethics Committee (21/SC/0178) and the Health Research Authority Confidentiality Advisory Group (20/CAG/0092).”

MethodsFind in source

“The study adhered to Good Clinical Practice guidelines, local regulations, and the ethical principles described in the Declaration of Helsinki.”

MethodsFind in source

PASSReviewer 2· 95% conf

Ethical approval is clearly documented with named committees, and consent procedures are described.

Evidence

“The trial protocol was approved by the South Central–Oxford C Research Ethics Committee (21/SC/0178) and the Health Research Authority Confidentiality Advisory Group (20/CAG/0092).”

MethodsFind in source

“The study adhered to Good Clinical Practice guidelines, local regulations, and the ethical principles described in the Declaration of Helsinki.”

MethodsFind in source

Sub-criteria

mycoplasma testingN/A

reagents identifiedADEQUATE

organisms identifiedN/A

antibodies identifiedN/A

cell line authenticationN/A

software tools identifiedADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 85% conf

The investigational product (epinephrine and amiodarone) is identified, and statistical software is specified.

Evidence

paraphrase[Table 2]

“Epinephrine | Administered- – no. (%) | 2866 (94.3%) | 2836 (93.2%) | 5702 (93.8%) | Dose (mg)- median (IQR) | 5.0 (3.1, 8.0) | 5.0 (3.0, 8.0) | 5.0 (3.0, 8.0)”

“Data management and analysis was performed with Statistical Analysis Systems (SAS), version 9.4.”

Statistical analysisFind in source

PASSReviewer 2· 85% conf

The investigational product (epinephrine) and other drugs are identified, and statistical software is specified.

Evidence

paraphrase[Table 2]

“Epinephrine | Administered- – no. (%) | 2866 (94.3%) | 2836 (93.2%) | 5702 (93.8%)”

“Data management and analysis was performed with Statistical Analysis Systems (SAS), version 9.4.”

Statistical analysisFind in source

Sub-criteria

tests namedADEQUATE

exact p valuesADEQUATE

effect sizes ciADEQUATE

data presentationADEQUATE

software identifiedADEQUATE

assumptions verifiedADEQUATE

mathematical plausibilityN/A

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

Statistical methods are appropriate and well-described, with exact p-values for the primary outcome and effect sizes with confidence intervals.

Evidence

ResultsFind in source

“0.880 (0.695, 1.113) | 0.945 (0.676, 1.322), p=0.741”

Table 3Find in source

“Data management and analysis was performed with Statistical Analysis Systems (SAS), version 9.4.”

Statistical analysisFind in source

PASSReviewer 2· 90% conf

Statistical methods are appropriate and well-described, with effect sizes and confidence intervals reported; p-values are exact where reported.

Evidence

ResultsFind in source

Table 3Find in source

“Data management and analysis was performed with Statistical Analysis Systems (SAS), version 9.4.”

Statistical analysisFind in source

Sub-criteria

code sharingN/A

accession numbersN/A

repository depositNOT REPORTED

data availability statementINADEQUATE

Per reviewer (2) — the votes behind the verdict

WARNReviewer 1· 80% conf

A data availability statement is present but vague, lacking a concrete access mechanism.

Evidence

“The protocol, developed by the trial investigators, has been published previously and is available, together with the statistical analysis plan, in the .”

MethodsFind in source

absence[Whole paper]

No repository deposit mentioned.

WARNReviewer 2· 80% conf

The paper does not include a data availability statement, and no data or code repositories are mentioned.

Evidence

absence[Entire paper]

No data availability statement is present in the paper.

Sub-criteria

funding coiADEQUATE

trial registrationADEQUATE

reporting guidelineINADEQUATE

methods completenessADEQUATE

all outcomes reportedADEQUATE

limitations discussedADEQUATE

conclusions proportionalADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

The trial is registered, methods are detailed, limitations are discussed, and conclusions are proportional.

Evidence

“Trial registration: ISRCTN14223494”

AbstractFind in source

Discussion ¶4Find in source

“This study was funded by the National Institute for Health and Care Research Health Technology Assessment programme (NIHR131105).”

FundingFind in source

PASSReviewer 2· 90% conf

The paper is transparent, with trial registration, detailed methods, discussion of limitations, and proportional conclusions.

Evidence

“Trial registration: ISRCTN14223494”

AbstractFind in source

“Our trial has several additional limitations. We did not collect information on resuscitation quality, because of the pragmatic nature of the trial and the challenges of collecting these data.”

Discussion ¶4Find in source

“This study was funded by the National Institute for Health and Care Research Health Technology Assessment programme (NIHR131105).”

FundingFind in source

Registered (1 ID: ISRCTN). No reporting guideline cited.

Broken references and links

1 finding · worst high

References checked against Crossref, OpenAlex and Retraction Watch for retractions and resolvability, plus declared data and code links probed for whether they resolve to content matching the paper.

Cites retracted workRecomputed

Checked 30 references by DOI: 28 verified — 1 retracted, 1 no DOI (shown, not verified).

Copyediting

5 minor

Wording, consistency and formatting errors that need correcting before submission.

No major wording or formatting errors. 5 minor suggestions below.

5 copyedit issues flagged: mostly consistency, clarity, typo.

Kaimen Rigor Action ItemsFinal pass before journal submission

1.
HIGHrigor
Correct the internal inconsistency in the total number of randomized participants: Table 1 header states N=6086 while the text and Table 2 state N=6082. Verify the correct total and update Table 1 accordingly.
An internal contradiction in the primary denominator undermines the credibility of the reported results and could warrant a correction.
2.
HIGHdata code
Add a clear data availability statement in the Methods or a dedicated section, specifying a managed-access route (e.g., via the Warwick Clinical Trials Unit data access committee) with conditions and timeframe.
The current statement is vague or missing, and a concrete mechanism is expected for patient-level trial data.
3.
HIGHreporting
Remove or replace the retracted citation: 'Intraosseous versus intravenous vascular access in upper extremity among adults with out-of-hospital cardiac arrest: cluster randomised clinical trial (VICTOR trial)' (DOI 10.1136/bmj-2024-079878).
Citing a retracted paper is a serious integrity issue that must be corrected.
4.
HIGHcopyedit
Fix the incomplete sentence in Methods, Trial design and oversight: 'available, together with the statistical analysis plan, in the .' should read 'available in the Supplementary Appendix.'
The placeholder text is a clarity issue that also affects the data availability statement.
5.
MEDIUMcopyedit
Correct the typo in author affiliations: 'North Eest Ambulance Service' should be 'North East Ambulance Service'.
A typo in an affiliation is a minor but visible error.
6.
MEDIUMreporting
Explicitly state adherence to the CONSORT reporting guideline in the Methods or provide a CONSORT checklist.
Explicitly mentioning CONSORT strengthens reporting transparency.
7.
MEDIUMreporting
Provide a CONSORT flow diagram as a figure to improve reporting transparency.
A flow diagram is a standard element of trial reporting that is currently missing.
8.
MEDIUMstatistics
Clarify the handling of missing data for the primary outcome in the statistical analysis section, specifying the variables used in the multiple imputation model.
The paper mentions multiple imputation but does not detail the imputation model, which is important for reproducibility.
9.
MEDIUMreporting
Provide a link or DOI to the full protocol and statistical analysis plan in the manuscript text.
The current reference is incomplete and should be made explicit for readers.
10.
LOWcopyedit
Rephrase the sentence in Methods, Statistical Analysis: 'We planned to recruit 15,000 patients. Based on PARAMEDIC2 trial data, 14972 patients were required' for clarity.
The sentence structure is awkward and could be clearer.
11.
LOWreporting
Consider reporting exact p-values for all secondary outcomes, even though confidence intervals are provided.
Exact p-values enhance statistical transparency.
12.
LOWreporting
Add a note on the generalizability of the findings given the early termination, possibly in the abstract.
Highlighting the early termination in the abstract would help readers interpret the results.

Full text (42,297 chars)Analyzed: Aug 16, 2026